In the news

Ken Stein, MD, senior vice president and global chief medical officer, discuss health inequities and Boston Scientific's work to improve access to care for underserved populations.

Boston Scientific presented a study at the 23rd American Society of Regional Anesthesia and Pain Medicine Meeting that demonstrates Fast-Acting Sub-Perception Therapy (FAST), with the WaveWriter spinal cord stimulation systems, as a breakthrough solution that significantly reduces chronic pain and improves patient outcomes with high satisfaction for up to 12 months, and no increase in opioid use during the primary endpoint interval.

Jodi Euerle Eddy, chief information and digital officer, shares the importance of interdepartmental collaboration in creating a culture of innovation that supports the investment, deployment and successful adoption of new technology.

As the number of people diagnosed with atrial fibrillation (AF) rises around the world, Ken Stein, MD, senior vice president and global chief medical officer and Nick Spadea-Annello, global president, Electrophysiology, along with industry experts, offer the Star Tribune perspective on the paradigm shift to pulsed field ablation for the treatment of AF, the explosive growth of the FARAPULSE™ Pulsed Field Ablation System, the competitive innovation race and the future of cardiac care.

Through interviews with senior executives and industry analysts, The Boston Globe explores how the combination of Boston Scientific’s acquisition strategy, in-house R&D and investment portfolio position the company for long-term success.